CHD2 (O14647) variants and mutations
CHD2 (also known as O14647) is a human protein-coding gene encoding an ATP-dependent chromatin remodeler protein. It remodels chromatin to regulate transcription and is particularly important for neuronal development and activity-dependent gene expression. Haploinsufficiency commonly causes developmental and epileptic encephalopathy, often with photosensitive seizures and intellectual disability. This analysis covers 2,008 CHD2 variants and mutations. Of these, 86% have computational variant effect predictions. Disease context includes developmental and epileptic encephalopathy 94, B-cell chronic lymphocytic leukemia, and complex neurodevelopmental disorder. Example CHD2 variants include M1T, M2I, and M2V.
Variant analysis overview
- Gene: CHD2
- Protein: O14647
- UniProt accession: O14647
- Organism: Homo sapiens
- Variants analyzed: 2008
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,815 unspecified-consequence records; 102 missense variants; 17 frameshift variants; 53 synonymous variants; 1 in-frame deletions; 11 stop-gained variants; 2 splice-region variants; 2 stop retained variant; 3 stop lost; 2 substitution
- Prediction scores: 1,725 variants have prediction scores (86% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: developmental and epileptic encephalopathy 94, B-cell chronic lymphocytic leukemia, complex neurodevelopmental disorder, lymphoid leukemia, Epileptic encephalopathy, hereditary disease, Intellectual disability, neurodegenerative disease, Seizure, epilepsy with myoclonic atonic seizures, autism spectrum disorder, Rolandic epilepsy.
Protein structure and variant hotspots
- Protein features: 4 domains; 1 binding sites; 9 post-translational modification sites.
- Structural context: 438 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CHD2 variants
Examples include M1T, M2I, M2V, M2L, M2T, M2R, R3G, R3I. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs193920953, ClinGen CA174163, ClinVar RCV000149041, MetaLR 0.60, MetaSVM -0.02, Uncertain significance, Prostate cancer
- M2I (p.Met2Ile), ExAC rs768049004, REVEL 0.49, MetaLR 0.71, Uncertain significance, Developmental and epileptic encephalopathy 94
- M2V (p.Met2Val), gnomAD 15-92901241-A-G, REVEL 0.44, MetaLR 0.68
- M2L (p.Met2Leu), gnomAD 15-92901241-A-T, REVEL 0.38, MetaLR 0.61
- M2T (p.Met2Thr), gnomAD 15-92901242-T-C, REVEL 0.52, MetaLR 0.69
- M2R (p.Met2Arg), gnomAD 15-92901242-T-G, REVEL 0.45, MetaLR 0.69
- R3G (p.Arg3Gly), Ensembl rs2052524430, REVEL 0.38, MetaLR 0.57
- R3I (p.Arg3Ile), TOPMed rs2052524459, gnomAD rs2052524459, REVEL 0.45, MetaLR 0.69
- R3T (p.Arg3Thr), TOPMed rs2052524459, gnomAD rs2052524459
- R3K (p.Arg3Lys), gnomAD 15-92901245-G-A, REVEL 0.33, MetaLR 0.48
- R3S (p.Arg3Ser), gnomAD 15-92904925-G-T, CADD 15.60, SIFT 0.01
- R3R (p.Arg3Arg), rs1264382376, gnomAD 15-92904925-G-A, CADD 15.90
- R3C (p.Arg3Cys), rs968209923, gnomAD 15-92904968-C-T, CADD 9.47, SIFT 0.15
- R3H (p.Arg3His), rs1261735474, gnomAD 15-92904969-G-A, CADD 4.58, SIFT 0.63
- N4K (p.Asn4Lys), rs750955957, ClinGen CA7747387, ClinVar RCV001901648, ExAC rs750955957, REVEL 0.29, MetaLR 0.51, Uncertain significance, Developmental and epileptic encephalopathy 94
- N4S (p.Asn4Ser), rs2052524504, ClinGen CA393892343, cosmic curated COSV59122, ClinVar RCV001349566, REVEL 0.23, MetaLR 0.45, Uncertain significance, Inborn genetic diseases; Developmental and epileptic encephalopathy 94
- N4D (p.Asn4Asp), gnomAD 15-92901247-A-G, REVEL 0.33, MetaLR 0.54
- K5R (p.Lys5Arg), gnomAD 15-92901249-TA-T, CADD 31.00
- K5N (p.Lys5Asn), gnomAD 15-92901252-G-T, REVEL 0.23, MetaLR 0.45
- K5E (p.Lys5Glu), gnomAD 15-92904917-A-G, CADD 16.20, SIFT 0.09
- D6N (p.Asp6Asn), gnomAD 15-92901253-G-A, REVEL 0.34, MetaLR 0.51
- D6H (p.Asp6His), gnomAD 15-92901253-G-C, REVEL 0.43, MetaLR 0.67
- D6E (p.Asp6Glu), gnomAD 15-92901255-C-A, REVEL 0.30, MetaLR 0.45
- D6D (p.Asp6Asp), gnomAD 15-92901255-C-T, CADD 12.90
- D6Y (p.Asp6Tyr), gnomAD 15-92904929-G-T, CADD 9.15, SIFT 0.03
- D6G (p.Asp6Gly), rs777729118, gnomAD 15-92904930-A-G, CADD 7.17, SIFT 0.09
- K7R (p.Lys7Arg), rs2052524601, ClinGen CA393892365, ClinVar RCV001222579, Ensembl rs2052524601, AlphaMissense 0.08, MetaLR 0.50, Uncertain significance, Developmental and epileptic encephalopathy 94
- S8C (p.Ser8Cys), TOPMed rs2052524639, REVEL 0.29, MetaLR 0.49
- S8I (p.Ser8Ile), TOPMed rs2052524671, MetaLR 0.48, MetaSVM -0.07
- S8N (p.Ser8Asn), gnomAD 15-92901260-G-A, REVEL 0.33, MetaLR 0.46
- S8S (p.Ser8Ser), rs1251726951, gnomAD 15-92901261-C-T, CADD 13.50
- S8R (p.Ser8Arg), gnomAD 15-92901261-C-A, REVEL 0.34, MetaLR 0.51
- Q9H (p.Gln9His), Ensembl rs1555435025, REVEL 0.37, MetaLR 0.52
- Q9K (p.Gln9Lys), ExAC rs755568618, gnomAD rs755568618, REVEL 0.20, MetaLR 0.47
- Q9R (p.Gln9Arg), ExAC rs779552225, gnomAD rs779552225, REVEL 0.28, MetaLR 0.45
- Q9Q (p.Gln9Gln), gnomAD 15-92901264-A-G, CADD 12.90
- Q9G (p.Gln9Gly), rs772808137, gnomAD 15-92904916-TAAAC, CADD 14.00
- Q9* (p.Gln9Ter), rs2052591236, gnomAD 15-92904920-C-T, CADD 12.60
- E10K (p.Glu10Lys), ExAC rs748824933, gnomAD rs748824933, REVEL 0.33, MetaLR 0.52
- E10V (p.Glu10Val), gnomAD rs1472693863, REVEL 0.32, MetaLR 0.50
- E10E (p.Glu10Glu), rs754725429, gnomAD 15-92901267-G-A, CADD 12.20
- E10G (p.Glu10Gly), gnomAD 15-92904927-A-G, CADD 12.10, SIFT 0.02
- E10A (p.Glu10Ala), gnomAD 15-92904927-A-C, CADD 11.70, SIFT 0.04
- E10D (p.Glu10Asp), rs2052591357, gnomAD 15-92904928-A-C, CADD 0.81, SIFT 0.11
- E11G (p.Glu11Gly), rs1411246213, ClinVar RCV004594910, AlphaMissense 0.16, MetaLR 0.68, Uncertain significance, Developmental and epileptic encephalopathy 94
- E11V (p.Glu11Val), gnomAD rs1411246213, MetaLR 0.68, MetaSVM 0.51
- E11del (p.Glu11del), rs772244385, gnomAD 15-92901264-AGAG-, CADD 21.70
- E11D (p.Glu11Asp), gnomAD 15-92901270-G-T, REVEL 0.23, MetaLR 0.43
- D12N (p.Asp12Asn), gnomAD rs1425971436, REVEL 0.34, MetaLR 0.51
- D12G (p.Asp12Gly), gnomAD 15-92901272-A-G, REVEL 0.41, MetaLR 0.52
- D12E (p.Asp12Glu), gnomAD 15-92901273-C-G, REVEL 0.29, MetaLR 0.38
- S13C (p.Ser13Cys), gnomAD 15-92901274-A-T, REVEL 0.32, MetaLR 0.39
- S13S (p.Ser13Ser), gnomAD 15-92901276-T-C, CADD 14.80
- S13F (p.Ser13Phe), rs2052591709, gnomAD 15-92904945-C-T, CADD 7.81, SIFT 0.00
- S14A (p.Ser14Ala), rs2052525047, ClinGen CA393892416, ClinVar RCV001317067, TOPMed rs2052525047, AlphaMissense 0.08, MetaLR 0.71, Uncertain significance, Developmental and epileptic encephalopathy 94
- S14L (p.Ser14Leu), NCI-TCGA Cosmic COSV5912, cosmic curated COSV59120, REVEL 0.42, MetaLR 0.74, Variant assessed as somatic; moderate impact.
- S14W (p.Ser14Trp), gnomAD 15-92901278-C-G, REVEL 0.44, MetaLR 0.78
- S14S (p.Ser14Ser), rs1163731878, gnomAD 15-92901279-G-A, CADD 13.70
- L15P (p.Leu15Pro), rs1060503522, ClinGen CA16614836, ClinVar RCV000464197, TOPMed rs1060503522, AlphaMissense 0.07, MetaLR 0.42, Uncertain significance, Developmental and epileptic encephalopathy 94
- L15R (p.Leu15Arg), rs1060503522, ClinGen CA393892423, ClinVar RCV003582349, AlphaMissense 0.07, MetaLR 0.42, Uncertain significance, Developmental and epileptic encephalopathy 94
- L15L (p.Leu15Leu), rs1009840698, gnomAD 15-92901282-A-G, CADD 13.40
- L15V (p.Leu15Val), rs1330847132, gnomAD 15-92901307-C-G, CADD 16.50
- L15I (p.Leu15Ile), gnomAD 15-92901307-C-A, CADD 16.20
- L15F (p.Leu15Phe), rs920434931, gnomAD 15-92901322-C-T, CADD 18.30
- L15H (p.Leu15His), gnomAD 15-92901323-T-A, CADD 19.40
- L15* (p.Leu15Ter), gnomAD 15-92901368-T-G, CADD 18.30
- L15W (p.Leu15Trp), rs1353693733, gnomAD 15-92904936-T-G, CADD 12.90, SIFT 0.00
- L15C (p.Leu15Cys), rs1206335333, gnomAD 15-92904940-CT-C, CADD 4.80
- L15Q (p.Leu15Gln), gnomAD 15-92905003-ACT-A, CADD 14.30
- H16N (p.His16Asn), gnomAD 15-92901283-C-A, REVEL 0.34, MetaLR 0.50
- H16Y (p.His16Tyr), gnomAD 15-92901283-C-T, REVEL 0.34, MetaLR 0.51
- H16Q (p.His16Gln), gnomAD 15-92901285-C-A, REVEL 0.26, MetaLR 0.42
- H16H (p.His16His), gnomAD 15-92901285-C-T, CADD 12.90
- H16I (p.His16Ile), gnomAD 15-92904912-CT-C, CADD 13.90
- H16D (p.His16Asp), gnomAD 15-92904914-C-G, CADD 16.50, SIFT 0.00
- S17N (p.Ser17Asn), TOPMed rs1170983948, gnomAD rs1170983948, REVEL 0.33, MetaLR 0.70
- S17R (p.Ser17Arg), gnomAD 15-92901288-C-A, REVEL 0.40, MetaLR 0.75
- N18S (p.Asn18Ser), rs1034044226, ClinGen CA274884110, ClinVar RCV001474557, TOPMed rs1034044226, REVEL 0.33, MetaLR 0.67, Likely benign, Developmental and epileptic encephalopathy 94
- A19T (p.Ala19Thr), NCI-TCGA TCGA novel, MetaLR 0.48, MetaSVM -0.46, Variant assessed as somatic; moderate impact.
- A19G (p.Ala19Gly), gnomAD 15-92901293-C-G, REVEL 0.16, MetaLR 0.53
- A19E (p.Ala19Glu), gnomAD 15-92901293-C-A, REVEL 0.34, MetaLR 0.47
- A19A (p.Ala19Ala), rs1412598141, gnomAD 15-92901294-A-G, CADD 14.70
- A19S (p.Ala19Ser), gnomAD 15-92904910-G-GA, CADD 18.60
- S20=, NCI-TCGA TCGA novel, Variant assessed as somatic; low impact.
- S20L (p.Ser20Leu), rs1057524801, ClinGen CA393892457, ClinVar RCV001500601, gnomAD rs1057524801, REVEL 0.41, MetaLR 0.71, Likely benign, Developmental and epileptic encephalopathy 94
- S20W (p.Ser20Trp), rs1057524801, ClinGen CA16606842, ClinVar RCV000433652, ClinVar RCV003766470, REVEL 0.46, MetaLR 0.76, Uncertain significance, Developmental and epileptic encephalopathy 94; not provided
- S20* (p.Ser20Ter), gnomAD 15-92901296-C-A, CADD 39.00
- S20S (p.Ser20Ser), gnomAD 15-92901297-G-C, CADD 18.20
- S21T (p.Ser21Thr), rs1596359879, ClinGen CA393892463, cosmic curated COSV59121, ClinVar RCV000995426, AlphaMissense 0.56, Uncertain significance, not provided
- S21N (p.Ser21Asn), gnomAD 15-92901299-G-A, REVEL 0.34, MetaLR 0.70
- S21S (p.Ser21Ser), gnomAD 15-92924321-T-C, CADD 16.60
- H22N (p.His22Asn), gnomAD 15-92924322-C-A, REVEL 0.07, MetaLR 0.41
- H22H (p.His22His), rs2141745833, gnomAD 15-92924324-C-T, CADD 8.04
- S23L (p.Ser23Leu), NCI-TCGA Cosmic COSV5912, cosmic curated COSV59120, Variant assessed as somatic; moderate impact.
- S23P (p.Ser23Pro), NCI-TCGA TCGA novel, MetaLR 0.73, MetaSVM 0.59, Variant assessed as somatic; moderate impact.
- A24G (p.Ala24Gly), TOPMed rs1436782484, MetaLR 0.44, MetaSVM -0.48
- A24A (p.Ala24Ala), rs764675794, gnomAD 15-92924330-C-T, CADD 9.76
- S25C (p.Ser25Cys), Ensembl rs2053017161
- S25I (p.Ser25Ile), gnomAD 15-92901307-C-CT, CADD 18.60
- S25* (p.Ser25Ter), gnomAD 15-92901311-C-A, CADD 17.60
- S25L (p.Ser25Leu), gnomAD 15-92901311-C-T, CADD 18.10
- S25S (p.Ser25Ser), rs778561242, gnomAD 15-92901312-A-G, CADD 20.90
- S25P (p.Ser25Pro), gnomAD 15-92924331-T-C, REVEL 0.30, MetaLR 0.71
- E26G (p.Glu26Gly), gnomAD 15-92901305-A-G, CADD 18.50
- E26D (p.Glu26Asp), rs780490876, gnomAD 15-92901305-AGC-A, CADD 15.60
- E26K (p.Glu26Lys), gnomAD 15-92924334-G-A, REVEL 0.30, MetaLR 0.69
- E27D (p.Glu27Asp), rs2053017198, ClinGen CA393895919, ClinVar RCV002020529, Ensembl rs2053017198, AlphaMissense 0.10, MetaLR 0.40, Uncertain significance, Developmental and epileptic encephalopathy 94
- E27G (p.Glu27Gly), gnomAD 15-92904999-A-G, CADD 19.40, SIFT 0.46
- E27E (p.Glu27Glu), rs986752119, gnomAD 15-92905000-A-G, CADD 18.00
- A28S (p.Ala28Ser), gnomAD 15-92901355-G-T, CADD 17.70
- A28G (p.Ala28Gly), rs908519850, gnomAD 15-92901356-C-G, CADD 18.90
- A28D (p.Ala28Asp), gnomAD 15-92901356-C-A, CADD 18.80
- A28V (p.Ala28Val), rs908519850, gnomAD 15-92901356-C-T, CADD 19.30
- A28E (p.Ala28Glu), gnomAD 15-92904987-C-A, CADD 14.30, SIFT 0.03
- A28A (p.Ala28Ala), rs1158234856, gnomAD 15-92904988-A-G, CADD 11.10
- S29L (p.Ser29Leu), ExAC rs752343848, TOPMed rs752343848, gnomAD rs752343848, REVEL 0.31, MetaLR 0.53
- S29F (p.Ser29Phe), rs555459805, gnomAD 15-92902194-C-T, CADD 16.30
- S29P (p.Ser29Pro), gnomAD 15-92902196-T-C, CADD 19.40
- S29S (p.Ser29Ser), rs781564863, gnomAD 15-92902198-T-C, CADD 20.30
- G30S (p.Gly30Ser), rs1243119782, ClinGen CA393895932, ClinVar RCV003582248, gnomAD rs1243119782, REVEL 0.12, MetaLR 0.45, Uncertain significance, Developmental and epileptic encephalopathy 94
- G30V (p.Gly30Val), rs1159397411, gnomAD 15-92904996-G-T, CADD 18.10, SIFT 0.01
- G30G (p.Gly30Gly), rs2053017360, gnomAD 15-92924348-T-C, CADD 8.65
- S31L (p.Ser31Leu), gnomAD 15-92924350-C-T, REVEL 0.39, MetaLR 0.76
- S31S (p.Ser31Ser), gnomAD 15-92924351-A-G, CADD 10.90
- D32N (p.Asp32Asn), rs7179364, gnomAD 15-92904992-G-A, CADD 15.50, SIFT 0.29
- D32Y (p.Asp32Tyr), gnomAD 15-92904992-G-T, CADD 15.20, SIFT 0.01
- D32E (p.Asp32Glu), rs955573131, gnomAD 15-92904994-T-G, CADD 14.10, SIFT 0.34
- D32V (p.Asp32Val), gnomAD 15-92924353-A-T, REVEL 0.34, MetaLR 0.59
- S33L (p.Ser33Leu), rs377012056, ClinGen CA7747442, ClinVar RCV000814417, ESP rs377012056, REVEL 0.44, MetaLR 0.75, Uncertain significance, Developmental and epileptic encephalopathy 94
- G34D (p.Gly34Asp), ExAC rs751460719, gnomAD rs751460719, REVEL 0.06, MetaLR 0.54
- G34R (p.Gly34Arg), gnomAD rs1204291805, MetaLR 0.62, MetaSVM 0.27
- G34L (p.Gly34Leu), gnomAD 15-92901330-C-CTT, CADD 12.60
- G34W (p.Gly34Trp), rs769211092, gnomAD 15-92901330-C-CT, CADD 12.60
- G34E (p.Gly34Glu), gnomAD 15-92901339-TG-T, CADD 8.71
- G34V (p.Gly34Val), gnomAD 15-92901341-G-T, CADD 11.70
- G34G (p.Gly34Gly), gnomAD 15-92901342-G-T, CADD 17.30
- G34* (p.Gly34Ter), gnomAD 15-92901343-G-T, CADD 18.60
- S35G (p.Ser35Gly), rs2053017567, ClinGen CA393895963, ClinVar RCV002795202, TOPMed rs2053017567, AlphaMissense 0.20, MetaLR 0.72, Uncertain significance, Developmental and epileptic encephalopathy 94
- S35S (p.Ser35Ser), rs1279999895, gnomAD 15-92924363-T-C, CADD 13.20
- Q36E (p.Gln36Glu), ExAC rs757227044, gnomAD rs757227044
- Q36L (p.Gln36Leu), rs1064794584, ClinGen CA16620037, ClinVar RCV000479088, ClinVar RCV000533538, REVEL 0.18, MetaLR 0.47, Uncertain significance, Developmental and epileptic encephalopathy 94; not provided
- Q36R (p.Gln36Arg), TOPMed rs1064794584, gnomAD rs1064794584, MetaLR 0.46, MetaSVM -0.42, Uncertain significance
- Q36V (p.Gln36Val), rs1271026888, gnomAD 15-92904976-TTC-T, CADD 11.70
- Q36K (p.Gln36Lys), gnomAD 15-92904980-C-A, CADD 11.30, SIFT 0.75
- S37L (p.Ser37Leu), cosmic curated COSV59122, gnomAD rs1255717695, REVEL 0.44, MetaLR 0.76
- S37T (p.Ser37Thr), Ensembl rs2053017731
- S37W (p.Ser37Trp), gnomAD rs1255717695, REVEL 0.51, MetaLR 0.76
- S37* (p.Ser37Ter), gnomAD 15-92924368-C-A, CADD 38.00
- S37S (p.Ser37Ser), rs371078680, gnomAD 15-92924369-G-A, CADD 10.40
- E38R (p.Glu38Arg), rs2035917320, gnomAD 15-92901339-T-TG, CADD 9.69
- E38K (p.Glu38Lys), rs2052526498, gnomAD 15-92901344-GA-G, CADD 11.20
- E38A (p.Glu38Ala), gnomAD 15-92901347-A-C, CADD 16.10
- E38G (p.Glu38Gly), rs1228024255, gnomAD 15-92901347-A-G, CADD 16.30
- E38E (p.Glu38Glu), gnomAD 15-92901348-A-G, CADD 19.30
- S39A (p.Ser39Ala), rs2052526585, gnomAD 15-92901352-T-G, CADD 20.40
- S39* (p.Ser39Ter), gnomAD 15-92901353-C-A, CADD 18.70
- S39L (p.Ser39Leu), gnomAD 15-92901353-C-T, CADD 19.20
- E40D (p.Glu40Asp), Ensembl rs2053017867, MetaLR 0.39, MetaSVM -0.54
- E40* (p.Glu40Ter), gnomAD 15-92924376-G-T, CADD 40.00
- E40E (p.Glu40Glu), gnomAD 15-92924378-G-A, CADD 10.40
- Q41R (p.Gln41Arg), gnomAD 15-92924380-A-G, REVEL 0.08, MetaLR 0.44
- Q41H (p.Gln41His), gnomAD 15-92924381-G-T, REVEL 0.07, MetaLR 0.38
- Q41Q (p.Gln41Gln), gnomAD 15-92924381-G-A, CADD 8.88
- G42E (p.Gly42Glu), gnomAD 15-92924383-G-A, REVEL 0.17, MetaLR 0.50
- S43R (p.Ser43Arg), Ensembl rs779858941, MetaLR 0.57, MetaSVM 0.14
- S43G (p.Ser43Gly), gnomAD 15-92924385-A-G, REVEL 0.18, MetaLR 0.55
- S43S (p.Ser43Ser), rs779858941, gnomAD 15-92924387-T-C, CADD 10.10
- P45T (p.Pro45Thr), Ensembl rs962845044, CADD 18.90
- P45S (p.Pro45Ser), rs2052526879, gnomAD 15-92901370-C-T, CADD 19.40
- P45H (p.Pro45His), gnomAD 15-92901371-C-A, CADD 17.70
- P45A (p.Pro45Ala), rs1191320279, gnomAD 15-92904947-C-G, CADD 8.53, SIFT 0.06
- P45L (p.Pro45Leu), rs779987344, gnomAD 15-92904948-C-T, CADD 10.70, SIFT 0.01
- P45P (p.Pro45Pro), rs878990709, gnomAD 15-92904949-A-G, CADD 1.04
- S47G (p.Ser47Gly), Ensembl rs1596379566, REVEL 0.09, MetaLR 0.45
- S47N (p.Ser47Asn), rs781140829, ClinGen CA7747445, ClinVar RCV003043475, ExAC rs781140829, REVEL 0.16, MetaLR 0.46, Uncertain significance, Developmental and epileptic encephalopathy 94
- S47T (p.Ser47Thr), ExAC rs781140829, TOPMed rs781140829, MetaLR 0.46, MetaSVM -0.51, Uncertain significance
- S47S (p.Ser47Ser), rs745812477, gnomAD 15-92924399-T-C, CADD 8.26
- G48G (p.Gly48Gly), gnomAD 15-92924402-A-G, CADD 9.78
- H49L (p.His49Leu), TOPMed rs1038860028, MetaLR 0.42, MetaSVM -0.27
- H49R (p.His49Arg), TOPMed rs1038860028, REVEL 0.08, MetaLR 0.41, Uncertain significance, Developmental and epileptic encephalopathy 94
Public CHD2 analysis runs
- CHD2 analysis run — CHD2 (2,008 variants) — completed 2026-08-19